The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
Open accessAbstract
During recent decades there have been remarkable advances and profound changes in cancer therapy. Many therapeutic strategies learned at the bench, including monoclonal antibodies and small molecule inhibitors, have been used at the bedside, leading to important successes. One of the most important advances in biology has been the discovery that small interfering RNA (siRNA) is able to regulate the expression of genes, by a phenomenon known as RNA interference (RNAi). RNAi is one of the most rapidly growing fields of research in biology and therapeutics. Much research effort has gone into the application of this new discovery in the treatment of various diseases, including cancer. However, even though these molecules may have potential and strong utility, some limitations make their clinical application difficult, including delivery problems, side effects due to off-target actions, disturbance of physiological functions of the cellular machinery involved in gene silencing, and induction of the innate immune response. Many researchers have attempted to overcome these limitations and to improve the safety of potential RNAi-based therapeutics. Nanoparticles, which are nanostructured entities with tunable size, shape, and surface, as well as biological behavior, provide an ideal opportunity to modify current treatment regimens in a substantial way. These nanoparticles could be designed to surmount one or more of the barriers encountered by siRNA. Nanoparticle drug formulations afford the chance to improve drug bioavailability, exploiting superior tissue permeability, payload protection, and the "stealth" features of these entities. The main aims of this review are: to explain the siRNA mechanism with regard to potential applications in siRNA-based cancer therapy; to discuss the possible usefulness of nanoparticle-based delivery of certain molecules for overcoming present therapeutic limitations; to review the ongoing relevant clinical research with its pitfalls and promises; and to evaluate critically future perspectives and challenges in siRNA-based cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics
Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., Sundaresan, G., Wu, A. M., Gambhir, S. S., & Weiss, S. (2005) · Science · doi:10.1126/science.1104274 · Cited by 7,790
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., & Behr, J. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,247
In vivo cancer targeting and imaging with semiconductor quantum dots
Gao, X., Cui, Y., Levenson, R. M., Chung, L. W. K., & Nie, S. (2004) · Nature Biotechnology · doi:10.1038/nbt994 · Cited by 4,772
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,291
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Gilbert, W. (1986) · Nature · doi:10.1038/319618a0 · Cited by 2,721
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370
Nonviral vectors for gene delivery
Mintzer, M. A., & Simanek, E. E. (2009) · Chemical Reviews · doi:10.1021/cr800409e · Cited by 2,366
Small silencing RNAs: an expanding universe
Ghildiyal, M., & Zamore, P. D. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2504 · Cited by 2,325
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149
Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation
Rosi, N. L., Giljohann, D. A., Thaxton, C. S., Lytton-Jean, A. K. R., Han, M. S., & Mirkin, C. A. (2006) · Science · doi:10.1126/science.1125559 · Cited by 1,988
Gilbert, W. (1986) · Nature · Cited by 1,941
Biodegradable luminescent porous silicon nanoparticles for in vivo applications
Park, J.-H., Gu, L., von Maltzahn, G., Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2009) · Nature Materials · doi:10.1038/nmat2398 · Cited by 1,897
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“117,118 However, some disadvantages must be overcome before they can be used in vivo.”
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Imaging and drug delivery using theranostic nanoparticles
Janib, S. M., Moses, A. S., & MacKay, J. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.004 · Cited by 1,248
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,221
Passenger-Strand Cleavage Facilitates Assembly of siRNA into Ago2-Containing RNAi Enzyme Complexes
Matranga, C., Tomari, Y., Shin, C., Bartel, D. P., & Zamore, P. D. (2005) · Cell · doi:10.1016/j.cell.2005.08.044 · Cited by 1,211
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Strategies for silencing human disease using RNA interference
Kim, D. H., & Rossi, J. J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2006 · Cited by 1,078
RNA interference in adult mice
McCaffrey, A. P., Meuse, L., Pham, T.-T. T., Conklin, D. S., Hannon, G. J., & Kay, M. A. (2002) · Nature · doi:10.1038/418038a · Cited by 1,059
Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B., & McNeil, S. E. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800032f · Cited by 1,022
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity
Jackson, A. L., Burchard, J., Schelter, J., Chau, B. N., Cleary, M., Lim, L., & Linsley, P. S. (2006) · RNA · doi:10.1261/rna.25706 · Cited by 956
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
Sengupta, S., Eavarone, D., Capila, I., Zhao, G., Watson, N., Kiziltepe, T., & Sasisekharan, R. (2005) · Nature · doi:10.1038/nature03794 · Cited by 945
Xia, T., Kovochich, M., Liong, M., Meng, H., Kabehie, S., George, S., Zink, J. I., & Nel, A. E. (2009) · ACS Nano · doi:10.1021/nn900918w · Cited by 933
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Cell-specific targeting of nanoparticles by multivalent attachment of small molecules
Weissleder, R., Kelly, K., Sun, E. Y., Shtatland, T., & Josephson, L. (2005) · Nature Biotechnology · doi:10.1038/nbt1159 · Cited by 904
RNAi therapeutics: Principles, prospects and challenges
Aagaard, L., & Rossi, J. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.005 · Cited by 895
siRNA function in RNAi: A chemical modification analysis
CHIU, Y.-L., & RANA, T. M. (2003) · RNA · doi:10.1261/rna.5103703 · Cited by 860
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Kam, N. W. S., Liu, Z., & Dai, H. (2005) · Journal of the American Chemical Society · doi:10.1021/ja053962k · Cited by 784
Argonaute2 Cleaves the Anti-Guide Strand of siRNA during RISC Activation
Rand, T. A., Petersen, S., Du, F., & Wang, X. (2005) · Cell · doi:10.1016/j.cell.2005.10.020 · Cited by 784
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
Antisense oligonucleotides: basic concepts and mechanisms.
Dias, N., & Stein, C. A. (2002) · PubMed · Cited by 759
De Angelis, F., Gentile, F., Mecarini, F., Das, G., Moretti, M., Candeloro, P., Coluccio, M. L., Cojoc, G., Accardo, A., Liberale, C., et al. (2011) · Nature Photonics · doi:10.1038/nphoton.2011.222 · Cited by 736
Novina, C. D., & Sharp, P. A. (2004) · Nature · doi:10.1038/430161a · Cited by 724
(2007) · Wiley eBooks · doi:10.1002/9783527621323 · Cited by 717
Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F., & Aigner, A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302425 · Cited by 716
In vivo imaging of siRNA delivery and silencing in tumors
Medarova, Z., Pham, W., Farrar, C., Petkova, V., & Moore, A. (2007) · Nature Medicine · doi:10.1038/nm1486 · Cited by 697
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695 · cited 1×
“Observations from clinically approved nanoparticle formulations suggest that lipidic carriers (Doxil ® ) and covalent coupling with albumin (Abraxane ® ) 65 are viable strategies for siRNA delivery.”
Self-citationEngineering targeted viral vectors for gene therapy
Waehler, R., Russell, S. J., & Curiel, D. T. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2141 · Cited by 687
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
Tasciotti, E., Liu, X., Bhavane, R., Plant, K., Leonard, A. D., Price, B. K., Cheng, M. M.-C., Decuzzi, P., Tour, J. M., Robertson, F., et al. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2008.34 · Cited by 668
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
Rozema, D. B., Lewis, D. L., Wakefield, D. H., Wong, S. C., Klein, J. J., Roesch, P. L., Bertin, S. L., Reppen, T. W., Chu, Q., Blokhin, A. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703778104 · Cited by 658
siRNA delivery systems for cancer treatment
Oh, Y.-K., & Park, T. G. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.018 · Cited by 645
Breaking down the barriers: siRNA delivery and endosome escape
Dominska, M., & Dykxhoorn, D. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.066399 · Cited by 630
Bartlett, D. W. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj439 · Cited by 592
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 567
Molecular Basis for Target RNA Recognition and Cleavage by Human RISC
Ameres, S. L., Martinez, J., & Schroeder, R. (2007) · Cell · doi:10.1016/j.cell.2007.04.037 · Cited by 559
Dicing and slicing: The core machinery of the RNA interference pathway
Hammond, S. M. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.08.079 · Cited by 545
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
Tolia, N. H., & Joshua-Tor, L. (2007) · Nature Chemical Biology · doi:10.1038/nchembio848 · Cited by 461
Goldenberg, M. M. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88288-0 · Cited by 453
Lipid‐based nanotherapeutics for siRNA delivery
Schroeder, A., Levins, C. G., Cortez, C., Langer, R., & Anderson, D. G. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02189.x · Cited by 447
DeVincenzo, J., Lambkin-Williams, R., Wilkinson, T., Cehelsky, J., Nochur, S., Walsh, E., Meyers, R., Gollob, J., & Vaishnaw, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912186107 · Cited by 442
Layer-by-Layer Assembled Gold Nanoparticles for siRNA Delivery
Elbakry, A., Zaky, A., Liebl, R., Rachel, R., Goepferich, A., & Breunig, M. (2009) · Nano Letters · doi:10.1021/nl9003865 · Cited by 425
DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R. K., Rajeev, K. G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708285104 · Cited by 415
Proton-Sponge Coated Quantum Dots for siRNA Delivery and Intracellular Imaging
Yezhelyev, M. V., Qi, L., O’Regan, R. M., Nie, S., & Gao, X. (2008) · Journal of the American Chemical Society · doi:10.1021/ja800086u · Cited by 407
Development of a novel endosomolytic diblock copolymer for siRNA delivery
Convertine, A. J., Benoit, D. S. W., Duvall, C. L., Hoffman, A. S., & Stayton, P. S. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.10.004 · Cited by 406
Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells
Muratovska, A., & Eccles, M. R. (2004) · FEBS Letters · doi:10.1016/s0014-5793(03)01505-9 · Cited by 390
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels
Lee, H., Mok, H., Lee, S., Oh, Y.-K., & Park, T. G. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.011 · Cited by 365
Targeted drug delivery via folate receptors
Zhao, X., Li, H., & Lee, R. J. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.3.309 · Cited by 358
siRNA-based approaches in cancer therapy
Devi, G. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700931 · Cited by 353
Prospects of RNA interference therapy for cancer
Pai, S. I., Lin, Y.-Y., Macaes, B., Meneshian, A., Hung, C.-F., & Wu, T.-C. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302694 · Cited by 352
Oxygen Radical-Mediated Pulmonary Toxicity Induced by Some Cationic Liposomes
Dokka, S., Toledo, D., Shi, X., Castranova, V., & Rojanasakul, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007504613351 · Cited by 349 · cited 1×
“123 Chemical additives could improve their formulation and reduce cell toxicity, thus making liposomes safer.”
Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver
Akinc, A., Goldberg, M., Qin, J., Dorkin, J. R., Gamba-Vitalo, C., Maier, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Manoharan, M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.36 · Cited by 323
Sustained Small Interfering RNA Delivery by Mesoporous Silicon Particles
Tanaka, T., Mangala, L. S., Vivas-Mejia, P. E., Nieves-Alicea, R., Mann, A. P., Mora, E., Han, H.-D., Shahzad, M. M. K., Liu, X., Bhavane, R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3931 · Cited by 316
Efficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 309
Polymers for siRNA Delivery: Inspired by Viruses to be Targeted, Dynamic, and Precise
Wagner, E. (2012) · Accounts of Chemical Research · doi:10.1021/ar2002232 · Cited by 308
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 297
Gene therapy progress and prospects: synthetic polymer-based systems
Schaffert, D., & Wagner, E. (2008) · Gene Therapy · doi:10.1038/gt.2008.105 · Cited by 277
Gold, Poly(β-amino ester) Nanoparticles for Small Interfering RNA Delivery
Lee, J.-S., Green, J. J., Love, K. T., Sunshine, J., Langer, R., & Anderson, D. G. (2009) · Nano Letters · doi:10.1021/nl9009793 · Cited by 276
Cells preferentially grow on rough substrates
Gentile, F., Tirinato, L., Battista, E., Causa, F., Liberale, C., di Fabrizio, E. M., & Decuzzi, P. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.06.016 · Cited by 276
PEG conjugated VEGF siRNA for anti-angiogenic gene therapy
Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W., & Park, T. G. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.023 · Cited by 273
Polymeric nanoparticles for siRNA delivery and gene silencing
Patil, Y., & Panyam, J. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.09.039 · Cited by 270
Castanotto, D., Sakurai, K., Lingeman, R., Li, H., Shively, L., Aagaard, L., Soifer, H., Gatignol, A., Riggs, A., & Rossi, J. J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm543 · Cited by 269
First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder
Leachman, S. A., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L., Boucher, K. M., Hansen, C. D., Eliason, M. J., Srivatsa, G. S., Kornbrust, D. J., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.273 · Cited by 265
The response of mammalian cells to double-stranded RNA
Gantier, M. P., & Williams, B. R. G. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.06.016 · Cited by 265
Merritt, W. M., Lin, Y. G., Spannuth, W. A., Fletcher, M. S., Kamat, A. A., Han, L. Y., Landen, C. N., Jennings, N., De Geest, K., Langley, R. R., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn024 · Cited by 257
Hatakeyama, H., Ito, E., Akita, H., Oishi, M., Nagasaki, Y., Futaki, S., & Harashima, H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.008 · Cited by 254
Polymer therapeutics as nanomedicines: new perspectives
Duncan, R. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.05.507 · Cited by 254
Spatiotemporal controlled delivery of nanoparticles to injured vasculature
Chan, J. M., Zhang, L., Tong, R., Ghosh, D., Gao, W., Liao, G., Yuet, K. P., Gray, D., Rhee, J.-W., Cheng, J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914585107 · Cited by 253
Therapeutic potential of RNA interference against cancer
Takeshita, F., & Ochiya, T. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00234.x · Cited by 236
Ptasznik, A., Nakata, Y., Kalota, A., Emerson, S. G., & Gewirtz, A. M. (2004) · Nature Medicine · doi:10.1038/nm1127 · Cited by 228
Cationic lipids enhance siRNA-mediated interferon response in mice
Ma, Z., Li, J., He, F., Wilson, A., Pitt, B., & Li, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.041 · Cited by 225
Gene delivery by cationic lipid vectors: overcoming cellular barriers
Zuhorn, I. S., Engberts, J. B. F. N., & Hoekstra, D. (2007) · European Biophysics Journal · doi:10.1007/s00249-006-0092-4 · Cited by 224
Martinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222406899 · Cited by 210
Polymers in Small-Interfering RNA Delivery
Singha, K., Namgung, R., & Kim, W. J. (2011) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0293 · Cited by 198
Knocking down Disease with siRNAs
Dykxhoorn, D. M., & Lieberman, J. (2006) · Cell · doi:10.1016/j.cell.2006.07.007 · Cited by 197
International Journal of Chemical Engineering
(2022) · International Journal of Chemical Engineering · doi:10.1155/8293 · Cited by 196
(2008) · Focus on Catalysts · doi:10.1016/s1351-4180(08)70340-4 · Cited by 192
Quantum dots to monitor RNAi delivery and improve gene silencing
Chen, A. A. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni188 · Cited by 186
Localized and Sustained Delivery of Silencing RNA from Macroscopic Biopolymer Hydrogels
Krebs, M. D., Jeon, O., & Alsberg, E. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9037615 · Cited by 183
Small RNA: can RNA interference be exploited for therapy?
Wall, N. R., & Shi, Y. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14637-5 · Cited by 180
Efficient siRNA Delivery with Non-viral Polymeric Vehicles
Kim, W. J., & Kim, S. W. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9774-1 · Cited by 166
Oishi, M., Nakaogami, J., Ishii, T., & Nagasaki, Y. (2006) · Chemistry Letters · doi:10.1246/cl.2006.1046 · Cited by 159
Targeted Delivery Systems for Oligonucleotide Therapeutics
Yu, B., Zhao, X., Lee, L. J., & Lee, R. J. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9096-1 · Cited by 158
MicroRNAs as biomarkers for CNS cancer and other disorders
Smaele, E. D., Ferretti, E., & Gulino, A. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.103 · Cited by 155
Self-citationFusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes
Oliveira, S., VANROOY, I., Kranenburg, O., Storm, G., & Schiffelers, R. M. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.11.050 · Cited by 155
Small RNAs derived from longer non-coding RNAs
Röther, S., & Meister, G. (2011) · Biochimie · doi:10.1016/j.biochi.2011.07.032 · Cited by 153
Research progress on siRNA delivery with nonviral carriers
Gao, Y., Liu, X., & Li, X. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s17040 · Cited by 147
In Vivo Sustained Release of siRNA from Solid Lipid Nanoparticles
Lobovkina, T., Jacobson, G. B., González-González, E., Hickerson, R. P., Leake, D., Kaspar, R. L., Contag, C. H., & Zare, R. N. (2011) · ACS Nano · doi:10.1021/nn203745n · Cited by 142
siRNA applications in nanomedicine
Tokatlian, T., & Segura, T. (2010) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.81 · Cited by 139
Porous silicon as drug carrier for controlled delivery of doxorubicin anticancer agent
Vaccari, L., Canton, D., Zaffaroni, N., Villa, R., Tormen, M., & Fabrizio, E. M. D. (2006) · Microelectronic Engineering · doi:10.1016/j.mee.2006.01.113 · Cited by 131
RNAi for Treating Hepatitis B Viral Infection
Chen, Y., Cheng, G., & Mahato, R. I. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9504-0 · Cited by 130
The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides
Chirilă, T. V., Rakoczy, P. E., Garrett, K. L., Lou, X., & Constable, I. J. (2002) · Biomaterials · doi:10.1016/s0142-9612(01)00125-9 · Cited by 127
Targeted Delivery of Small Interfering RNA: Approaching Effective Cancer Therapies
Pirollo, K. F., & Chang, E. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5810 · Cited by 121
Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita
Leachman, S. A., Hickerson, R. P., Hull, P. R., Smith, F. J. D., Milstone, L. M., Lane, E. B., Bale, S. J., Roop, D. R., McLean, W. H. I., & Kaspar, R. L. (2008) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2008.04.003 · Cited by 119
Gartel, A. L., & Kandel, E. (2006) · Biomolecular Engineering · doi:10.1016/j.bioeng.2006.01.002 · Cited by 117
Potential clinical applications of siRNA technique: benefits and limitations
Chen, S., & Zhaori, G. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02400.x · Cited by 107
RNAi: a potential new class of therapeutic for human genetic disease
Seyhan, A. A. (2011) · Human Genetics · doi:10.1007/s00439-011-0995-8 · Cited by 104
The Effective Dispersion of Nanovectors Within the Tumor Microvasculature
Decuzzi, P., Causa, F., Mauro Ferrari, B., & Netti, P. A. (2006) · Annals of Biomedical Engineering · doi:10.1007/s10439-005-9072-6 · Cited by 102
Five Years of siRNA Delivery: Spotlight on Gold Nanoparticles
Lytton‐Jean, A. K. R., Langer, R., & Anderson, D. G. (2011) · Small · doi:10.1002/smll.201100761 · Cited by 93
Novel modes of protein–RNA recognition in the RNAi pathway
Lingel, A., & Sattler, M. (2005) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2005.01.010 · Cited by 92
Yagi, N., Manabe, I., Tottori, T., Ishihara, A., Ogata, F., Kim, J. H., Nishimura, S., Fujiu, K., Oishi, Y., Itaka, K., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3945 · Cited by 92
RNAi and Gene Therapy: A Mutual Attraction
Grimm, D., & Kay, M. A. (2007) · Hematology · doi:10.1182/asheducation-2007.1.473 · Cited by 86
Cationic Polymer Based Nanocarriers for Delivery of Therapeutic Nucleic Acids
Nimesh, S., Gupta, N., & Chandra, R. (2011) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2011.1313 · Cited by 82
Controlled delivery of antisense oligonucleotides: a brief review of current strategies
Zhao, X., Pan, F., Holt, C. M., Lewis, A. L., & Lu, J. R. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902992894 · Cited by 82
Concepts in in vivo siRNA delivery for cancer therapy
Gondi, C. S., & Rao, J. S. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21790 · Cited by 75
Nanoporous Surfaces as Harvesting Agents for Mass Spectrometric Analysis of Peptides in Human Plasma
Gaspari, M., Cheng, M. M., Terracciano, R., Liu, X., Nijdam, A. J., Vaccari, L., Fabrizio, E. M. D., Petricoin, E. F., Liotta, L. A., Cuda, G., et al. (2006) · Journal of Proteome Research · doi:10.1021/pr050417+ · Cited by 75
Nucleic Acid Carriers Based on Precise Polymer Conjugates
Troiber, C., & Wagner, E. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200251r · Cited by 73
RNA interference: Implications for cancer treatment
Masiero, M., Nardo, G., Indraccolo, S., & Favaro, E. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.12.004 · Cited by 71
Peptide‐Loaded Solid Lipid Nanoparticles Prepared through Coacervation Technique
Gallarate, M., Battaglia, L., Peira, E., & Trotta, M. (2011) · International Journal of Chemical Engineering · doi:10.1155/2011/132435 · Cited by 69
Koldehoff, M., Steckel, N. K., Beelen, D. W., & Elmaagacli, A. H. (2007) · Clinical and Experimental Medicine · doi:10.1007/s10238-007-0125-z · Cited by 69
Whelan, J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03547-6 · Cited by 64
Baker, M. (2010) · Nature · doi:10.1038/4641225a · Cited by 62
Solid polymeric microparticles enhance the delivery of siRNA to macrophages in vivo
Lee, S., Yang, S. C., Kao, C., Pierce, R. H., & Murthy, N. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp758 · Cited by 62
Curcio, A., Marotta, R., Riedinger, A., Palumberi, D., Falqui, A., & Pellegrino, T. (2012) · Chemical Communications · doi:10.1039/c2cc17223b · Cited by 60
Desai, A. A., Schilsky, R. L., Young, A. H., Janisch, L. A., Stadler, W. M., Vogelzang, N. J., Cadden, S., Wright, J. R., & Ratain, M. J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi178 · Cited by 59
Subramanya, S., Kim, S. S., Manjunath, N., & Shankar, P. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903448158 · Cited by 47
RNAi and cancer: Implications and applications.
Abdelrahim, M., Safe, S. H., Baker, C. H., & Abudayyeh, A. (2006) · PubMed Central · Cited by 36
RNA interference-based gene therapy for successful treatment of rheumatoid arthritis
Courties, G., Présumey, J., Duroux-Richard, I., Jørgensen, C., & Apparailly, F. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902926089 · Cited by 36
RNAi Silencing in Mouse Models of Neurodegenerative Diseases
Farah, M. H. (2007) · Current Drug Delivery · doi:10.2174/156720107780362276 · Cited by 35
Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery
Li, L., Wang, R., Wilcox, D. M., Zhao, X. B., Song, J. C., Li, X., Kohlbrenner, W. M., Fesik, S. W., & Shen, Y. (2011) · Gene Therapy · doi:10.1038/gt.2011.146 · Cited by 34
Comparison of novel delivery systems for antisense peptide nucleic acids.
Chiarantini, L., Cerasi, A., Fraternale, A., Millo, E., Benatti, U., Sparnacci, K., Laus, M., Ballestri, M., & Tondelli, L. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.013 · Cited by 33
siRNAs: Potential therapeutic agents against Hepatitis C Virus
Ashfaq, U. A., Yousaf, M., Aslam, M., Ejaz, R., Jahan, S., & Ullah, O. (2011) · Virology Journal · doi:10.1186/1743-422x-8-276 · Cited by 30
Peterson, C. O. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1011-x · Cited by 22
Knöpfel, T., & Akemann, W. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2010.163 · Cited by 21
Design and development of antisense drugs
Malik, R., & Roy, I. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.10.1189 · Cited by 19
Polymers in Small-Interfering RNA Delivery
Singha, K., Namgung, R., & Kim, W. J. (2011) · Oligonucleotides · doi:10.1089/oli.2011.0293 · Cited by 15
Cited by
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Nanooncology: The future of cancer diagnosis and therapy
Thakor, A. S., & Gambhir, S. S. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21199 · Cited by 588
Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier
Upadhyay, R. K. (2014) · BioMed Research International · doi:10.1155/2014/869269 · Cited by 528
Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment
García-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J., Melguizo, C., & López-Romero, J. M. (2019) · Nanomaterials · doi:10.3390/nano9040638 · Cited by 527
Molecular Mechanisms and Biological Functions of siRNA
Department of Biology, D. B., Dana, H., Chalbatani, G. M., Mahmoodzadeh, H., Gharagouzlo, E., Cancer Research Center, C. I. O. I., Karimloo, R., Department of Medicine, Z. M. S., Rezaiean, O., Moradzadeh, A., et al. (2017) · International Journal of Biomedical Science · doi:10.59566/ijbs.2017.13048 · Cited by 505
Metadata
- Authors
- Gulino, A.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2012-07
- Volume
- 7
- Pages
- 3637
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W1969287626
- Cited by
- 258
- References
- 165
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.